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A novel mutation was identified by direct sequencing 
of genomic polymerase chain reaction products in 
each of four Finnish erythropoietic protoporphyria 
families. All four mutations, including two deletions 
(751deIGAGAA and the first de IIOVO mutation, 
1122deIT) and two point mutations (286C---') T and 
343C---') T), resulted in a dramatically decreased 
steady-state level of the allelic transcript, since none 
of the mutations could he demonstrated by direct 
E rythropoie tic pro toporphyria (EPP) is an inherited dis-ease caused by defi cient ac tiv ity of ferroch elatase (hem e synthase; E. C.4.99 .1. 1) , a mitoch o ndrial en-zym e in the heme biosynthesis pathway (Poh- Fitz-patrick, 1978). Ferroche latase ca talyzes the last step o f 
hem e biosynthesis, the ch elation o f fe rrous iro n into pro toporphy-
rin IX to fo rm h em e, and thus overproduction of pro topo rphyrin is 
the m aj o r biochemical abnormali ty in E PP (Magnus el ai, 196 1) . 
The disease usually m anifests by acute ph o to reaction s of the skin 
already in childhood. Typical sympto m s are sting ing pain o r itchin g 
w ith subsequent sw elling and erythem a of the sun-exposed ski.n, 
but chro nic skin ch an ges m ay also appear (Po h-Fitzpatrick, 1978) . 
In addition, th e skin symptoms m ay be accompanied by potentiall y 
fa tal hepato biliaJ'y complica tio n s in 5-25% o f patients (Blo omer et 
al,1 97 5) . 
Inheritan ce of EPP is conside red autosomal dominant with the 
variable pene trance based o n clini cal and biochemical analysis, and 
more recently on mol ecular gene tical studies of EPP patie nts alld 
the ir relatives (Lynch and Miedler , 1965; Donaldson el ai, 1967; 
R eed et ai , 1970; Schneider-Yin et ai, 1994) ; howeve r, inh etitance 
of an autosomal recessive trait (Went and Klasen , 1984, Lamoril el 
ai, 1991; Sarkany el ai, 1994a) or a multiple gene sys tem (No rri s el 
ai, 1990) h ave also been proposed. T hus, the m o de o f inheritan ce 
is still uncertain and m ay in volve differen t m echanism s in individua l 
families. 
T he fe rroche la tase gen e has been ass igned to chro m osom e 
18(q21.3) based on ill silll h ybridization of the corresponding 
cDNA (Brenn er et ai, 1992) . I. T he cDNA for th e fe rrochelatase 
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sequencing of the amplified cDNAs synthesized from 
total RNA extracted from patients ' lymphoblast cell 
lines. Because the assays of the ferrochelatase a c tivity 
and erythrocyte protoporphyrin identity asymptom-
atic patients poorly, the DNA-based d e monstration 
of a mutation is the only reliable way to screen 
individuals for the dise ase-associated mutation. Key 
lVol'd: pOl'pl'Yl'ia. ] Invest Del'llwtol 106:346-350, 1996 
gene is 1269 bp in size, and only o ne iso form of the enzym e has 
been de m o nstra ted (Nakahashi cl ai , 1990) . T he gen e is a t least 45 
kb in size and contains 11 ex ons (Take tani "I ai, 1992 ). 
Sin ce the sequence o f the cD N A and the exon-intron boundaries 
of the gene ha ve been available , it h as fac ilitated the identification 
of the mutations amon g EPP patien ts, and so far 13 muta tio ns in the 
fe rrochelatase gene , including po in t mutatio ns and de le ti ons , ha ve 
been identifi ed (Schneide r-Yin et ai , 1994; Lamo lil el (/1, 1991 ; 
Sarkan y el ai, 1994a ,b ; Brenner el ai, 1992; Na ka hashi el ai, 1992; 
1993a ,b ; Todd ct ai, 1993; W ang et ai , 1993; M agness cl ai, 1994). 
In this study, we describe fo ur 11 0velmu ta tio ll s in the fe rrochelatase 
gene ide n tifi ed fro m fo ur of the 10 bi ochemicall y and clinica ll y w ell 
characte6 zed EPP fa milies known in Finl and . 
MATEIUA L AND M ETHODS 
Patients Twenty-one patients. either symptomatic or asymptomatic. 
representing 10 known Fin nish EPP f:lmilies. and their 11 healthy relatives 
wcre investigated by DNA analysis. T hc cl inical diagnosis of symptomatic 
EPP was based on typical phocosensitivit), of the s!cin, on .increased 
erythrocyte protoporpbyrin (Li el nl , 1986) and on low re ticlliocyte ferro-
chelatase ac tivity (Pasanen " I il l , 1992). T he e"cretion of fccal and urine 
porphyrins was dctermincd b), hjgh-perfo rmance liquid chromatography (Li 
el nl , 1986) , and liver transaminases were measured to evaluate the early 
signs of Ij ver damage. 
DNA, RNA Extraetion~ , and eDNA Synthesis DN A was e"tracted 
from whj te blood cells (Higuchi , 1989) and total RNA was extractcd from 
E pste in- BaIT v iru s- tra n sfect cd lYl11pho biastoid cdl lin es (C hi rw illg et nl. 
1979; Sambrook 1'1 "I, '1989). Complcmenta ry DNA was syn thesizcd frolll 
pati ents ' total lymphoblast RNA by SuperScri pt II RN asc reverse trall-
scriptasc (G ibco-BR.L, Gaithersburg, MD) using random hc"amcrs. 
Single-strand Conformation Polymorphism (SSCP) Analysis and 
Sequencing of the Genomic DNA and eDNA Each c"on of the 
ferrochdatase gene was amplified (Mullis and Faloona , 1987) using primers 
designed co anneal to the target sequences of the e"on-intron boundary sites 
of each c"on (Taketani " I "I, 1992) allowing the amplification of eKons 
individually. T he DN A (300 ng/samplc) was ampli ficd using specific 
prim ers, 30 pmol each in 50 I ..d of solution. T he tempera ture profi le in the 
polymcrase chain reac tion was 2 min at 94 °C fo r the fir st denatu ring step. 
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Figure 1. Pedigrees of the four EPP families studied .• alld •. 
affected indi viduals with manifest disease; IiJ and (), asympto matic individ-
ua ls ca rrying the a([ected gene; D and 0 , unallccccd famil y member. D, 1iJ. 
and • . ma le; O . (). and ., female. 
then 30 s at 94°C. 30 s at 52-56°C. and 30 s at 72°C for 30 cycles. For the 
SSCP anal yses DNA sa mples were radiolabeled during the polymerase chain 
reaction by addi ng 1 }.LC i of a J2 p dCTP (Amersham. Buckinghamshire 
U. K.) into a reaction tube. Single-strand separation gel electro phoresis w ith 
ge ls containing 5 or 1 O'X. glycero l was perforn1l!d at room tell1perature. and 
a gel with no glyce rol was run in the cold room (I-la ta el nl, 1990) . For 
sequencing the genomic DNA. one of the primer pairs was biotinylated at 
its 5' end, and the polym erase chain reaction products were purified with 
streptav idin-coated lI1icro bcads (Fluoricon; Ide"", Westbrook, M~E). For 
scquencing the cDNA , the amplified samples were run in a low-melting 
aga rose ge l, and the fra gl1ll!l1ts were cut out of the ge l and purified using 
Magic PC R. Prep Kit (Promega. Madison. WI). T he products wcre directl y 
se quenced using the didco"y chain termination method (Sanger d nl. 1977) . 
Amplifica tion and di rec t sequcncing bo th with sense and anti-sense primers 
was repeated at least tl ve independent times from a patient's D NA samples 
as a rnutati o ll site was ana lyzed . 
Computer-Based Predictions The hydrophobicity predictions for the 
m utated ferrochc\;'tasc chains werc carried Ollt b), the method of C hou and 
Fasman (1978) . "nd the secondary structures we re predicted by the method 
of Hopp and W oods ('198 1) . 
RESULTS 
Identified Mutations [n Family 1 (Fig 1), di.rec t sequ e ncing of 
three patients' amplified genomic DNA demonstrated a d e letio n of 
five (GAGAAGAGAA) nucle otides in tande m repeat b eguUling 
from nucl eotide 751 (or 7S6)G ill exon 7 (Fig 2). The d e letio n 
cau sed a fra m eshift and was pre dic ted to result in a premature stop 
cod o n 70 a mino acids apa rt from the de letion site (Fig 2, Table I) . 
T h e d e letion was confirmed b y restri c tion cleavage since it a lso 
abolished the Mi>oJi restric tion e nzyme site. The SSCP analys is of 
exon 7 demonstrated two migrating bands, and the reamplification 
and direct sequencing of th e b ands c ut o ut individu ally showed two 
diffe re nt sequences, th e n o rmal and t he delete d se quence (data not 
s bown). T he deletion could be d e monstrated from the patients' 
relatives (Table II), and the two EPP famili es originating from the 
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Figure 2. Nucleotide sequences of two patients' genomic DNA 
demonstrating deletions in the ferrochelatase gene. Upper seq llel/ce. 
11 22dclT in e"on 1 0; lall'eI'seqllel/ce. 75 1 (or756)delGAGAA in c" on 7. 
same area in eastern Finland were later found , by a ge n ealogical 
se arc h in church registers, to b e related to each other as well (Fig 
1). 
In Family 2, sequen cing of a patient's genomic DNA d e mon-
strated a d e letion of nucleotide 1122T in ex o n 10 (Fig 2) . This 
lead s to a frameshift and was a lso predicted to result in a prel~l ature 
stop codon 24 amino acid s apart from the d e le tion site (Table I) . 
SSCP an alysis was performe d in two diffe ren t e lectrophoresis 
conditions but no abnormal migration w as o bta ined. The 
11 22delT re presents a de 1/ 0110 event sUlce it could not b e deplon-
strated from the amplifie d genomic DNA of oth er members in the 
family (Fig 1, Table II). T h e pate rnity of the p atient was con-
Table I. Characteristics of the Four Mutatiol1s in the 
Ferrochelatase Gene 
Mutation-Specific 
E"on Mutation Outcomc cDNA R estriction Enzyme 
3 286C->T Q 96X Ava il 
4 343C->T R115X 
7 751dclGAGAA Frame shift Mbo" 
10 I 122dclT ham!! shift 
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Table II. The DNA Analysis and Biochemical Results of the Members of Four EPP Families 
Mutation 
Screening 
Family 1 751delGAGAA 
Patient 2 (22 y) +" 
Patient 3 (18 y) + 
Father + 
Mother 
Patient 1 (7 y) + 
Father 
Mother + 
Grandmother + 
Family 2 1l22delT 
Patient (11 y) + 
Father 
Mother 
Sister 
Family 3 286C ..... T 
Patient (9 y) + 
Mother 
Grandfather 
Family 4 343 C ..... T 
Patient (33 y) + 
Father + 
Mother 
Grandfather' ND 
tI +. mutation positive; - . mutation negative. 
r. +, mi1d; ++. moderate; +++. severe . 
Ii Mean of two (0 five measUrements . 
• 1 ND. not done. 
, Dead. 
Photosensitivity 
+ +" 
++ 
+++ 
+ 
+ + 
+ ++ 
+ 
finned with 99.94% certainty using DNA fingerprint analysis 
(Helminen et ai, 1992). 
In Family 3, sequencing of a patient's genomic DNA demon-
strated a point mutation, 286C~T, in exon 3 (Fig 3; Tables I, II). 
The mutation was confirmed by cleavage with the A,laH restriction 
enzyme. In Family 4, sequencing of a patient's genomic DNA 
demonstrated a point mutation 343C~T in exon 4 (Fig 3; Tables 
I, II) . 
None of the four mutations were found among the other six 
unrelated EPP patients or among 20 unrelated healthy Finnish 
controls. In addition, only one species of the cDNAs showing 
normal sequences could be demonstrated from the patients' ampli-
fied cDNA synthesized from total RNA of their lymphoblast lines . 
Three known polymorphic sites (-23C~T [Nakahashi ct ai, 
1992], 287A->G [Nakahashi e/ ai, 1990; Sarkany et ai, 1994b], 
798G~C [Nakahashi ct ai, 1993bJ) were studied among the normal 
Finnish population and EPP patients, and the allelic frequencies did 
not differ between the groups studied, except in the case of the 
-23C~T polymorphic site; a T all ele was more frequent among 
EPP patients (total 82 all eles studied, p = 0.01). The haplotyping 
analysis ofl0 EPP families demonstrated that four potential haplo-
types associated with the symptomatic disease. A 287A~G base 
change in exon 3 (W96R), an arginine at amino acid 96 was much 
more common than glutamic acid among the Finnish popu lation, 
indicating that it is a rare polymorphic site in western populations 
(Lamoril el ai, 1991; Nakahashi ct ai, 1990; Sarkany el ai, 1994b). 
Clinical an4 Biochemical Characteristics of Patients with 
Identified Mutations The results of the biochemical assays of 
the patients and their relatives are presented in Table II. Seven 
patients had manifest EPP. Cutaneous photosensitivity occurred 
already in infancy in the case of the severe clinical phenotype, and 
in early childhood in the case of moderate or mild disease form. The 
intensity and onset of photosensitivity varied within the families, 
and showed no clear mutation-specific correlation. No signs ofliver 
complications were found in any of the patients. 
Ferrochclatasc Fecal 
Activity Erythrocyte Protoporphyrin 
(6.0-22.0 pl110l Protoporphyrin (0-130 Ill11oI/g 
hcmc/h/l06 retic) (200 - 1010 nM) dry weight) 
0.6 23,800' 69 
0.2 26,800 121 
2.2 1,010 NO" 
5.1 727 NO 
0.6 45,400' 258 
11.5 635 ND 
1.4 1,600 NO 
2.3 '1.200 NO 
1.2 18 ,100 85 
17.3 324 NO 
7.4 423 NO 
3.0 663 NO 
2.5 28,800 157 
14.1 364 NO 
NO ND NO 
0.4 75 ,600 1204 
2.1 1.400 23 
3.6 423 ND 
3.6 4,875 229 
The results in the assays of reticulocyte ferrochelatase activity 
were markedly decreased in every patient having a manifest disease. 
Some overlap of the results, however, could be shown among 
asymptomatic patients and healthy relatives. The eryth rocyte pro-
toporphyrin concentration correlated well with the skin symptoms, 
while in the asymptomatic patients the protoporphyrin values were 
only marginally elevated . The excretion of fecal protoporphyrin 
was increased in a few patients and poorly cOlTelated with the 
clinical state. 
DISCUSSION 
Four novel mutations including a first de 11.0'/ 0 mutation, two 
deletions and two point mutations, were identified in the ferroche-
latase gene among families representing 40% of all known EPP 
families in Finland . In addition, all four mutations resulted in a 
dramatically decreased steady-state level of the al lelic transcript, 
since none of the mutations could be demonstrated by direct 
sequencing of the ampJjfied cDNAs synthesized from total RNA 
extracted £i'om patients' lymphoblast ceD lines, the technique that 
typically requires some 20-30'Yo of the mutant trallScript to be 
present. Non-sense and frameshift mutations have been demon-
strated to associate with a dramatic decrease of cytoplasmic mRNA, 
and it is generally considered that the closer a termination codon is 
to the 3' end of a gene, the higher the level of the transcript 
(Cooper, 1993). Our findings on the termination mutations in the 
ferrochelatase gene, however, were not in complete accordance 
with this" 5' -3 ' positional effect." The reduction of the level of 
mRNA can be affected by transcription rate, processing, or trans-
port of RNA to cytoplasm; thus, several mechanisms can be 
responsible for the deficiency of the mutated mRNA species 
(Cooper, 1993) . None of the mutations were found in the ferro-
chelatase pseudogene (Whitcom be cf ai, 1994) excluding erroneous 
conclusions of the results. 
EPP usually has an autosomal dominant pattern of inheritance 
with variable penetrance, although some authors have suggested 
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F igurc 3. Nuclcotidc scqucncics of two paticnts ' gcnomic DNA 
demonstrating point mutations in thc fcrrochclatasc gcnc. Upper 
seqlll!lIcc, 286C--+T(Q96X) ill CXO II 3; IOli lcr seq lleIlC/!, 343C--+T(Rl15X) ill 
exoll 4. 
oth er modes of inheritance (Went el ai, 1984; Lamoril el ai, 1991; 
Sarkany cl ai, 1994a; Norris el ai, 1990). Suggestions for autosoma l 
dominant or recessive pattern of inhe ritance have both been based 
on the results of the assays of the ferroche la tase activity and on 
more recent molecular genetical stud ies ofEPP fam ilies. In Families 
1 and 4 in Fig 1, DNA analysis suggests autosol1lal dominant 
pattern of inheritance o f the disease . In both f:lm iLi es, the results of 
the assays of ferrochelatase activity showed relatively low valu es in 
several family m embers, which is in accordan ce with the results 
presented by other groups (Norris cl ai, 199 0; Sarkany el a/, 1994b) . 
T h e re ticu lo cyte ferrochelatase activ ity was extremely low (l ess 
than 10%) among o ur sympto matic EPP patients , corresponding to 
the residual activity reported from other protoporphyric ti ssues 
(10 -50°1./) (Brenner el ai, 1992) . T he results in the assays suggest 
a utosomal recessive pattern of inheritance in these fa milies, but no 
other mutations were found w hen over 88'/':, of the coding region 
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and exon-intron bo wldari es of their genomic DNA was sequenced . 
Moreover, regarding Fa mil y 1., w hich has three patien ts in two 
separate branches of the pedigree, it would be very unlikely to have 
additionall11utations in different branches simultaneously, unless an 
additional common rearrangement would affect the fe lTochelatase 
activity. 
All mutations have been fa mily specific, and thus EPP has been 
demonstrated to be heterogeneous at the m o lecular level despite of 
the relative uniformity of the c1inica] phenotype. AU om' symptom-
atic patien ts with different mutations have had characteristic pho-
tosensitivity with no signs of li ve r fai lure. For the present, it seem s 
to be difti cult to predict the onset or severi ty of cutaneous o r Li ve r 
disease based only on a mutation analysis beca use of c1 ini ca.l variety 
within the fam ilies and the small number of the patients anal yzed . 
More patient data ha s to be analyzed fo r the final conclu sions of the 
genotype-phenotype correlation of EPP. 
T he dramatic decrease in th e ferrochela tase activity and high 
erythrocyte protoporphyrins are usually characteristic in symptom-
atic EPP patients, but the biochemical m ethods poorly recognize 
asymptomatic individua ls carrying dIe aftccted gene . Thus, the 
demonstra tion of a mutatio n in the ferrochelatase gene is conve-
nient and the o nly reliabl e wa y to screen asymptomatic indi viduals 
in families whose mutation has been identi fied . 
T h;s slIId y (/Ins SJlpported b)' grnJltsji'Olll t.he Emil A nltollclI Fo" ",fnt;(lII, III(' Pnlll" 
FOII"dl1licHl, ,he IIlSlnllltCII,mi lllJl R('scafch FOIllH/micHI, 'he AradeHl)' oj Fi"lnlld nnd 
the UII;ClCfS ;/Y (~r He!s;lIk;. 
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